


FIG. 1A

11: PMA (100nM) + Rp-8-Br-cGMP (1μM)



- 1: Calphostin C (500nM), PKC inhibitor 2: Rp-8-Br-PET-cGMP (10µM), PKG inhibitor
- 3: LY83583 (50μM), GC-S inhibitor 4: KT5720 (500nM), PKA inhibitor






FIG. 2A



SUBSTITUTE SHEET (RULE 26)







Fig. 3A SUBSTITUTE SHEET (RULE 26)






Fig. 3B SUBSTITUTE SHEET (RULE 26)





FIG. 4A







FIG. 4B SUBSTITUTE SHEET (RULE 26)

FIG. 5A






FIG. 5B SUBSTITUTE SHEET (RULE 26)





FIG. 5C



**SUBSTITUTE SHEET (RULE 26)** 






FIG. 7


SUBSTITUTE SHEET (RULE 26)

WO 03/000027 PCT/US02/22270 13/18




SUBSTITUTE SHEET (RULE 26)





SUBSTITUTE SHEET (RULE 26)

Fig. 11



Treatments

MPO Secretion from LPS-Primed Human Neutrophils







Fig. 17







## This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:
□ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
COLOR OR BLACK AND WHITE PHOTOGRAPHS
GRAY SCALE DOCUMENTS
LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
OTHER:

## IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.